We have used an infectious cDNA clone of equine arteritis virus (EAV) and reverse genetics technology to further characterize the neutralization determinants in the GP5 envelope glycoprotein of the virus. We generated a panel of 20 recombinant viruses, including 10 chimeric viruses that each contained the ORF5 (which encodes GP5) of different laboratory, field, and vaccine strains of EAV, a chimeric virus containing the N-terminal ectodomain of GP5 of a European strain of porcine reproductive and respiratory syndrome virus, and 9 mutant viruses with site-specific substitutions in their GP5 proteins. The neutralization phenotype of each recombinant chimeric/mutant strain of EAV was determined with EAV-specific monoclonal antibodies and EAV strain-specific polyclonal equine antisera and compared to that of their parental viruses from which the substituted ORF5 was derived. The data unequivocally confirm that the GP5 ectodomain contains critical determinants of EAV neutralization. Furthermore, individual neutralization sites are conformationally interactive, and the interaction of GP5 with the unglycosylated membrane protein M is likely critical to expression of individual epitopes in neutralizing conformation. Substitution of individual amino acids within the GP5 ectodomain usually resulted in differences in neutralization phenotype of the recombinant viruses, analogous to differences in the neutralization phenotype of field strains of EAV and variants generated during persistent infection of EAV carrier stallions.
Introduction
Equine viral arteritis (EVA) is a respiratory and reproductive disease of horses that occurs throughout the world (Timoney and McCollum 1993; Timoney et al., 1986 Timoney et al., , 1987 . Equine arteritis virus (EAV), the causative agent of EVA, is an enveloped, positive-stranded RNA virus (Snijder, 2001) . EAV is the prototype virus in the family Arteriviridae, genus Arterivirus in the order Nidovirales (Cavanagh, 1997) . The EAV genome is approximately 12.7 kb and includes nine open reading frames (ORFs; Snijder, 2001; Snijder and Meulenberg, 1998) . The two most 5V-proximal ORFs (1a and 1b) occupy approximately three-quarters of the genome and encode two replicase polyproteins (1a and 1ab; de Vries et al., 1997; Snijder, 2001; Snijder and Meulenberg, 1998) . The remaining seven ORFs (2a, 2b, and 3 -7) are in the 3V-proximal quarter of the genome and encode seven structural proteins (de Vries et al., 1992; Snijder et al., 1999; Wieringa et al., 2003) . The EAV particle is 40-60 nm in diameter with an icosahedral core (diameter 25 -35 mm) that consists of the nonsegmented RNA genome and the nucleocapsid protein N (14 kDa; encoded by ORF7). The EAV envelope contains two principal proteins, specifically, the GP5 major envelope glycoprotein (30 -44 kDa; encoded by ORF5) and the unglycosylated membrane protein M (17 kDa; encoded by ORF6). The M and GP5 proteins form a disulfide-linked heterodimer that is critical for their maturation and for virus infectivity Snijder et al., 2003) . In addition, the EAV envelope contains a heterotrimer of three minor membrane glycoproteins designated as GP2b, GP3, and GP4 (25, 36 -42, and 28 kDa; encoded by ORFs 2b, 3, and 4, respectively; Wieringa et al., 2003) and an unglycosylated envelope protein E (8 kDa; encoded by ORF2a; Snijder et al., 1999) .
There is only one serotype of EAV; however, field strains differ in their virulence and neutralization phenotype (Balasuriya et al., 1997 (Balasuriya et al., , 1999a (Balasuriya et al., , 1999b (Balasuriya et al., , 2002 Hedges et al., 1999; Patton et al., 1999; Timoney and McCollum, 1993) . Animals that recover from EAV infection or those that are vaccinated with either inactivated or attenuated strains of EAV develop neutralizing antibodies and are resistant to subsequent challenge with EAV (Doll et al., 1957 (Doll et al., , 1968 McCollum 1986) . The GP5 protein expresses the known neutralization determinants of the virus (Balasuriya et al., 1993 (Balasuriya et al., , 1995a (Balasuriya et al., , 1995b (Balasuriya et al., , 1997 Chirnside et al., 1995 , Deregt et al., 1994 , Glaser et al., 1995 . We previously identified four neutralization sites (A -D) in the amino-terminal ectodomain of GP5 by comparative amino acid sequence analyses of a large number of neutralization-resistant viral variants and field isolates of EAV (Balasuriya et al., 1995a (Balasuriya et al., , 1995b (Balasuriya et al., , 1997 . We also recently have demonstrated that authentic post-translational modification and conformational maturation of recombinant GP5 occurs only in the presence of the M protein, and that this interaction is necessary for induction of anti-EAV neutralizing antibodies in mice and horses (Balasuriya et al., 2000 (Balasuriya et al., , 2002 .
The availability of an EAV reverse genetics system allowed us for the first time to directly assess the influence on virus neutralization of specific changes in the GP5 sequence while keeping the sequence of the rest of the viral genome constant and thus excluding the influence of variation in other viral proteins. In this report, we definitively confirm that the GP5 ectodomain contains the major neutralization epitopes of EAV, and that amino acids within the proposed four major neutralization sites of GP5 contribute to the formation of both linear and conformational epitopes in the amino-terminal ectodomain of the GP5 glycoprotein of EAV. The data clearly show that the neutralization phenotype of a virus derived from an infectious cDNA clone was altered by changing either the entire GP5 or specific amino acids within the amino-terminal ecotodomain of this protein.
Results and discussion

Generation of GP5 chimeric and mutant viruses
To characterize the neutralization determinants of EAV, a panel of 20 recombinant viruses was produced using the EAV infectious cDNA clone pA45 (Dobbe et al., 2001 ) as the backbone as described under Material and methods (Table 1) . The pA45 clone is a derivative of the pEAV030 infectious cDNA clone of EAV (van Dinten et al., 1997) . This panel included 10 chimeric viruses that each contained the ORF5 of a different laboratory, field, or modified live virus (MLV) vaccine strain of EAV, a single chimeric virus that contained the N-terminal ectodomain of GP5 of a European strain of Porcine reproductive and respiratory syndrome virus (PRRSV; Dobbe et al., 2001) , and 9 recombinant viruses with individual site-specific nucleotide (nt) substitutions in ORF5 (Figs. 1, 2a, and b and Table 1 ).
In vitro transcripts derived from chimeric or mutated genomic cDNA clones were transfected into BHK-21 cells by electroporation. An immunofluorescence staining assay for expression of EAV nonstructural (nsp3) and structural Balasuriya et al., 1997. d Balasuriya et al., 1995a. (N) proteins at 12 -20 h after transfection of recombinant RNA confirmed that in vitro transcripts were infectious (data not shown). The cells transfected with each recombinant transcript showed 90 -100% cytopathic effect (CPE) after 72-120 h, and virus stocks were made from these tissue culture fluids (TCF). To demonstrate the genetic stability of each recombinant virus, viral RNA was extracted from the TCF and ORF5 and flanking regions of ORF4 and 6 were directly sequenced to obtain the consensus sequence. Most recombinant viruses were genetically stable and maintained their neutralization phenotype after repeated cell culture passage (see below).
Neutralization phenotype of the GP5 chimeric viruses
A panel of well-characterized monoclonal antibodies (MAbs) and polyclonal antisera to EAV (Table 2 ) was used to compare the neutralization phenotype of each of the 11 chimeric viruses (each with a unique GP5; Fig. 2a ) with that of the A45 virus derived from an infectious cDNA clone (Tables 3a and b ). The data confirm that the ectodomain of GP5 is critical to the neutralization of EAV. For example, the 5r10B4 chimeric virus that lacks amino acids 62 -101 of the GP5 ectodomain was not neutralized by any of the MAbs ( < 32), nor by two of the polyclonal equine antisera ( < 8) that neutralized the A45 virus. Similarly, a chimeric virus A45.C2 (Dobbe et al., 2001) in which the EAV GP5 ectodomain was replaced by the ectodomain of the corresponding PRRSV protein was not neutralized by any of the MAbs nor by four of the polyclonal equine antisera. A GP5 ectodomain deletion mutant (A45-80.4; Snijder et al., 2003 ) that lacks amino acids 52-79, including the single GP5 N-glycosylation site (Asn-56) of the A45 virus, was not neutralized by one of the polyclonal antisera (anti-GP5/ M) that neutralized the A45 virus to high titer. Further, the A4-80.4 deletion mutant was neutralized to a significantly lower titer by four other polyclonal equine sera as compared to the A45 virus. Thus, the GP5 ectodomain contains major neutralization sites of EAV, although the fact that viruses that lack neutralization sites B (amino acid 61) and portions of neutralization sites C (amino acids 67-90) and D (amino acids 99 -106) were neutralized to variable titers by some of the polyclonal equine antisera confirms the presence of other minor neutralizing epitopes on EAV. These data are consistent with a recent study that demonstrated that a deletion mutant of EAV that lacked the immunodominant region of GP5 (amino acids 66-112) induced neutralizing antibodies in ponies, but convalescent sera from these ponies only weakly neutralized two other strains of EAV (Castillo-Olivares et al., 2003) . Thus, neutralization site C (amino acids 67 -90) contains the major neutralizing epitopes of EAV that are recognized by horses although, as described below, there likely is considerable conformational interaction of the four neutralization sites (A -D) in the amino-terminal ectodomain of GP5.
The substitution of ORF5 in the pA45 cDNA clone with the ORF5 derived from individual laboratory, field, and MLV vaccine strains of EAV usually altered the neutralization phenotype of the A45 virus into that of the parental virus from which the substituted ORF5 was derived, although there were some important exceptions (Tables 3a  and b ). For example, although all chimeric viruses with ORF5 derived from laboratory strains of EAV (5rUCD, 5r6D10, and 5r10B4) had a similar neutralization phenotype as that of the parental virus (UCD, EM6D10, and DEM10B4.3, respectively) from which their ORF5 was derived, these three chimeric viruses were all resistant to neutralization by MAb 1H7, whereas their parental viruses were neutralized by this MAb. MAb 1H7 recognizes a conformation-dependent epitope at amino acid 49 (site A) of the GP5 protein (Balasuriya et al., 1997 ) and all of these chimeric viruses have an aspartic acid residue at this position as do their parental viruses. The chimeric viruses differ from their respective parents in that their M protein is derived from the A45 virus, which also is not neutralized by MAb 1H7. Thus, the failure of MAb 1H7 to neutralize these three chimeric viruses indicates that another virus protein, likely the M protein, must interact with GP5 to ensure presentation of the epitope at site A in neutralizing conformation. We previously have shown that the M protein is critical to conformational maturation of GP5 (Balasuriya et al., 2000) , however, substitution of either the entire ORF6 (which encodes the M protein) or specific nucleotides in ORF6 of recombinant viruses will be required to demonstrate unequivocally that the M protein influences the expression of some conformation-dependent neutralization epitopes in the GP5 protein.
The MAbs used in this study recognize both linear and conformation-dependent epitopes localized to amino acids 49, 61, 69, 99, 102, 103, and 104 of the GP5 protein. These amino acids largely were conserved among the various viruses (Table 2 and Fig. 2; Balasuriya et al., 1995a Balasuriya et al., , 1995b Balasuriya et al., , 1997 , and the neutralization phenotype of most of the parental and their respective chimeric viruses with the MAbs was similar to that of the A45 virus (Table 3a ). There were important differences, however, which confirm the conformational interaction of neutralization sites A -D in the GP5 ectodomain. For example, the GP5 protein of the MLV vaccine and its chimeric virus (5rVAC) had an amino acid substitution (as compared to A45) at position 104 (Asp > Gly) and were consistently neutralized to a lower titer by MAb 5G11 which recognizes an epitope formed by amino acids 102 and 104 (Table 3a ). The amino acid at position 102 was not changed in the 5rVAC virus, but the substitution at 104 (Gly) was sufficient to alter the neutralization phenotype of this virus. In contrast, the 5rKY84 recombinant virus was unaltered at positions 102 and 104, but had multiple amino acid substitutions in neutralization sites B (61) and C (79 and 81) and was neutralized by MAbs 5G11 to the same titer as 5rVAC. This suggests that amino acid substitutions in sites B and C exert a conformational influence on neutralization site D. This conformational influence exerted by sites B and C is further confirmed by MAb 10H4 (recognizes an epitope at amino acids 102 and 103) which neutralized 5rVAC to the same titer as the parental A45 virus (4096), but neutralized the 5rKY84 recombinant virus (which is unaltered at positions 102 and 103) to a lower titer (1024).
Further evidence of the conformational interaction of the various neutralization sites of EAV (A -D) was evident from results obtained with MAbs 1H9, 6A2, and 7D4. These three MAbs recognize the same or overlapping conformation-dependent epitope(s) formed by amino acid 69 and other amino acids in this region (Balasuriya et al., 1997) . Amino acid substitutions such as Lys > Gln or Lys > Glu at position 61 (5rKY84, 5rIL93, and 5rCA95) or Thr > Glu at position 67 (5rWA97) influenced the neutralization by these Balasuriya et al., 1999a Balasuriya et al., , 1999b three MAbs. The close interaction between amino acids 61 and 69 is confirmed by the 5rKY84 virus which has amino acid substitutions at both of these positions (Lys > Gln-61 and Leu > Pro-69) yet is still neutralized by MAb 6A2 ( Fig.  2a and Table 3a ). In contrast, MAb 6A2 failed to neutralize the 5rVAC virus, which has only a single substitution at position 69 (Leu > Pro). Furthermore, the substitution of amino acid 67 (Thr > Glu) in the 5rWA97 virus may have allowed it to escape neutralization by MAb 6A2, suggesting that there also is a conformational interaction between amino acids 67 and 69. Together, these data indicate that amino acid substitutions in neutralization sites B and C can exert conformational changes on distant neutralization epitopes; for example, amino acid substitutions at 61 and 67 can alter the epitope at position 69 recognized by MAbs 1H9 and 7D4, resulting in the resistance to neutralization of the 5rKY84, 5rIl93, and 5rCA95 viruses to these two MAbs ( Fig. 2a and Table 3a) . Similarly, the chimeric viruses with different GP5 proteins from field isolates and MLV vaccine strains of EAV were neutralized to different titers by individual polyclonal horse antisera (Table 3b) , and the GP5 proteins of these viruses had amino acid substitutions within neutralization sites B and C as compared to the A45 virus ( Fig. 2a ). In summary, amino acid substitutions at amino acids 61 (site B) and 67-90 (site C) of the GP5 protein influence the expression of conformational neutralizing epitopes, and similar changes are likely critical to generating antigenic variation among field strains of EAV.
Neutralization phenotype of viruses with site-specific substitutions in GP5
To further evaluate the significance of individual amino acid residues in the four major neutralization sites in the Nterminal ectodomain of GP5, we introduced nucleotide substitutions specifying single amino acid changes in the GP5 ectodomain into chimeric infectious cDNA clones containing ORF5 of the ATCC, UCD, and MLV vaccine strains of EAV (Table 1) . MAbs and polyclonal antisera usually neutralized individual recombinant viruses to the same titer as their respective parental viruses (5rATCC, 5rUCD, and 5rVAC; Tables 4a and b ). However, substitution of specific amino acids sometimes altered the neutralization phenotype of individual recombinant viruses to one or more of the MAbs or polyclonal antisera (Tables 4a and  b ). For example, the 5rATCC D79N [Asp > Asn substitution at amino acid 79 (site C)] virus was neutralized to a considerably higher titer (>4096) with MAb 7E5 than was its parental virus 5rATCC (512). Similarly, the exchange of aspartic acid (Asp) to asparagine at (Asn) amino acid 49 (site A) significantly altered the neutralization of both 5rATCC D49N and 5rUCD D49N by MAbs 7E5 and 9F2, as compared to their parental viruses (Table 4a ). MAbs 7E5 and 9F2 both recognize epitopes in neutralization site D (amino acids 99 -106). Interestingly, this same amino acid substitution (Asp > Asn-49) substantially reduced the neutralization of 5rUCD D49N by MAb 1H9, which recognizes an epitope that includes amino acids 69 (within site C) and 99 -102 (within site D). Together, these data suggest that amino acid 49 (Site A) influences the conformation of neutralization sites C (recognized by MAb 1H9) and D (MAbs 7E5 and 9F2). Similarly, the introduction of specific amino acid substitutions in neutralization sites A, B, and C sometimes altered the neutralization of the recombinant progeny viruses by polyclonal antisera (Table 4b) . Importantly, several of the single amino acid substitutions into site C of 5rATCC changed the neutralization phenotype of the progeny virus by some of the polyclonal equine antisera, confirming that key neutralizing epitopes recognized by these sera are in this region of the GP5 ectodomain.
The mutant virus (5rVAC046SDM) with amino acid substitutions at residues 100, 104, and 106 (Gly > Ser, Gly > Asp, Val > Met, respectively; site D) spontaneously reverted to its original amino acid at position 100 (Gly) during serial passage and was neutralized to a significantly higher titer by the MAb 5G11, which recognizes an epitope in site D (amino acids 102 and 104; Table 4a ). These amino acid changes did not alter the neutralization phenotype of the mutant virus with any of the polyclonal antisera. Interestingly, abrogation of the N-linked glycosylation site at amino acid 81 did not significantly affect the neutralization phenotype of the N81D virus (Tables 4a and b) . Similarly, two of the recombinant viruses with amino acid substitutions at residue 49 and 67 (5rATCC D49N and 5rATCC T67A) spontaneously mutated during serial passage and lost the N-linked glycosylation site at amino acid 81 without affecting their neutralization phenotype. Together, these data suggest that the second potential N-linked glycosylation site at amino acid 81 does not influence the neutralization phenotype of EAV.
In summary, data presented in this study unequivocally prove that the GP5 ectodomain contains critical determinants Table 3a Neutralization titers a of monoclonal antibodies against parental and chimeric strains of EAV a Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 cell monolayers against 200 TCID 50 of virus. Significant differences in neutralization phenotype as compared to the A45 virus are boxed. The chimeric viruses with different neutralization phenotype from their respective parental viruses are shown within the hatched box. b Parental-original virus strain. c Chimera-chimeric virus with ORF5 from the respective parental virus inserted into the pA45 infectious cDNA clone of EAV. d MAb to the nucleocapsid (N) protein of EAV was used as a negative control. e MAb to the nonstructural protein 1 (nsp1) of EAV was used as a negative control. of EAV neutralization. The importance of the four major neutralization sites within the N-terminal ectodomain of EAV was confirmed by exchange of GP5 among the various viruses and by the substitution of individual amino acids within critical regions of GP5. The data further confirm that individual neutralization sites (A -D) interact with one another to form conformation-dependent epitopes, and that the interaction of GP5 with the unglycosylated M protein likely is critical to expression of some epitopes in neutralizing conformation (Fig. 3) . The manipulation of the GP5 proteins of the various recombinant viruses often resulted in only subtle differences in their neutralization phenotype, analogous to differences in the neutralization phenotype of field strains of EAV (Balasuriya et al., 1997 (Balasuriya et al., , 1999a (Balasuriya et al., , 1999b Edwards et al., 1999; Hedges et al., 1999; Westcott et al., 1995) . A high proportion of EAV-infected stallions become persistently infected carriers and continue to shed the virus in their semen for long periods of time (Balasuriya et al., , 1999a (Balasuriya et al., , 1999b (Balasuriya et al., , 2004 Hedges et al., 1999; Timoney and McCollum 1993 , Timoney et al., 1986 , 1987 . Novel genetic variants with distinct neutralization phenotypes arise during persistent infection of carrier stallions, and the altered neutralization phenotype of these variants is correlated with amino acid changes in neutralization sites B and C of the GP5 protein (Balasuriya et al., 1999a (Balasuriya et al., , 1999b Hedges et al., 1999) . Thus, data presented in this study are consistent with the hypothesis that variation within the GP5 N-terminal ectodomain that is generated during persistent infection of carrier stallions leads to the emergence of EAV strains of different neutralization phenotype (Balasuriya et al., 1999a (Balasuriya et al., , 1999b Hedges et al., 1999) .
Material and methods
Cells and viruses
Baby hamster kidney cells (BHK-21; ATCC CCL10) were maintained in Eagle's medium (EMEM) supplemented with 10% fetal bovine serum (FBS; Hyclone Laboratories, Inc.), 10% tryptose phosphate broth, and 1% penicillin and streptomycin. Rabbit kidney 13 (RK-13; ATCC CCL 37) cells were maintained in EMEM supplemented with 10% calf serum (Hyclone Laboratories, Inc.) and antibiotics. The passage histories of four field isolates of EAV (KY84, IL93, WA97, and CA95), two prototype laboratory strains [ATCC (ATCC VR-796), UCD], the A45 recombinant virus derived from an EAV infectious cDNA clone (pA45), and the modified live virus (MLV) vaccine strain (ARVAC, Fort Dodge Laboratories) as well as two neutralization resistant variant viruses [escape mutant (EM); EM6D10 and DEM10B4.3] have been previously described (Table 1;   Table 3b Neutralization titers a of polyclonal equine antisera against parental and chimeric strains of EAV a Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 cell monolayers against 200 TCID 50 of virus.
Significant differences in neutralization phenotype as compared to the A45 virus are boxed. b Original virus strain. c Chimeric virus with ORF5 from the representative parental virus inserted into the pA45 infectious cDNA clone of EAV. Balasuriya et al., 1995a Balasuriya et al., , 1995b Balasuriya et al., , 1997 Balasuriya et al., , 1998 Balasuriya et al., , 1999a Balasuriya et al., , 1999b Dobbe et al., 2001 , van Dinten et al., 1997 .
Monoclonal antibodies and polyclonal anti-sera
The development and characterization of a panel of 12 neutralizing monoclonal antibodies to GP5 (MAbs 5G11, 6D10, 7E5, 9F2, 10F11, 10H4, 1H7, 1H9, 5E8, 6A2, 7D4, and 10B4) and non-neutralizing monoclonal antibodies to the nucleocapsid protein (N; MAb 3E2) and nonstructural protein 1 (nsp1 [MAb 12A4]) of EAV have been previously described ( Table 2 ; Balasuriya et al., 1993 Balasuriya et al., , 1995a Balasuriya et al., , 1995b Balasuriya et al., , 1997 MacLachlan et al., 1998; Wagner et al., 2003) . The production and characterization of mono-specific rabbit antipeptide serum to nsp3 has been previously reported . Anti-EAV strain-specific equine sera (Table 2) were obtained by either experimental inoculation of horses (EAV ATCC, KY84, IL-93, NVSL, and 030H) or by vaccination with a recombinant vaccine (anti-GP5/M) and subsequent challenge with the KY84 field strain (anti-GP5/M post challenge with KY84; Balasuriya et al., 2002) . Table 4a Neutralization titers a of MAbs against chimeric and related strains of EAV with site-specific substitutions in GP5 a Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 cell monolayers against 200 TCID 50 of virus. Significant differences in neutralization phenotype as compared to the respective parental virus are boxed. b Viruses with ORF5 from EAV ATCC (5rATCC), MLV vaccine (5rVAC), and UCD (5rUCD) inserted into the pA45 infectious cDNA clone. c Viruses with site-specific substitutions in ORF5 of the various parental viruses. d MAb to the nucleocapsid (N) protein of EAV was used as a negative control. e MAb to the nonstructural protein 1 (nsp1) of EAV was used as a negative control.
Table 4b
Neutralization titers a of polyclonal equine sera against chimeric and related strains of EAV with site-specific substitutions in GP5 a Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 cell monolayers against 200 TCID 50 of virus. Significant differences in neutralization phenotype as compared to the respective parental virus are boxed. b Viruses with ORF5 from EAV ATCC (5rATCC), MLV vaccine (5rVAC) and UCD (5rUCD) inserted into the pA45 infectious cDNA clone. c Viruses with site-specific substitutions in ORF5 of the various parental viruses.
Plasmid construction and site-directed mutagenesis
The construction of the infectious cDNA clone pA45 was described previously (Dobbe et al., 2001) . In this construct, the small natural overlap between ORFs 4 and 5 was removed by insertion of a 24-nucleotide sequence containing a termination codon for ORF4, a unique AflII restriction site, and the ORF5 start codon (Fig. 1 ). This insertion resulted in the functional separation of ORF4 and 5, did not interfere with virus replication, and was stable upon repeated passaging in cell culture (de Vries et al., 2000) . The generation of the recombinant chimeric virus pA45.C2 and deletion mutant pA45-80.4 was previously described (Dobbe et al., 2001; Snijder et al., 2003) . In the first construct, the EAV GP5 ectodomain (amino acids 1-114) was replaced by that of European PRRSV (amino acids 1 -64), whereas in the second construct, amino acids 52-79 of the EAV GP5 ectodomain were deleted.
A shuttle vector (pS45) containing a BglII (10 704) -XhoI (12 845) fragment of the pA45 infectious cDNA clone was used to swap ORF5 from individual EAV strains to construct chimeric viruses. To facilitate cloning, a NotI restriction site was inserted downstream of the AflII site in the sequence separating ORF4 and 5 (Fig. 1) . Restriction digestion of this pS45 shuttle vector with NotI and XbaI allowed us to remove the original ORF5 and replace it with a new ORF5 sequence from another EAV strain, which was amplified from different EAV strains by RT-PCR using a 5V PCR primer containing a NotI site upstream of the ORF5 translation initiation codon ( Table 5 ). The 3V primer for the amplification of ORF5 included the natural XbaI site just downstream of the ORF5 sequence (nucleotide # 11 949) and also included 37 nucleo- Fig. 3 . Association of the GP5 and M proteins of EAV and predicted major neutralization sites in the N-terminal ectodomain of GP5. These two major envelope proteins are covalently linked by a disulfide bond (SS) formed between Cys-8 in the M protein and the Cys-34 in the GP5 protein (Snijder et al., 2003) . The conserved cysteine residues in the amino-terminal ectodomain of GP5 protein are indicated, as are the predicted conserved (Asn-56) and nonconserved (Asn-81) N-linked glycosylation sites in the GP5 ectodomain. tides of ORF6 to ensure that no mutations in this region would be included in the PCR fragment. ORF5 sequences from different EAV strains (Table 1) were RT-PCR-amplified and digested with restriction enzymes (NotI and XbaI) and ligated into the pS45 shuttle vector that had been digested with the same restriction enzymes. Next, the RT-PCR-derived insert was sequenced and the BglII -XhoI fragment corresponding to ORFs 4 to 7 and the genomic 3V end was transferred from chimeric pS45 shuttles to the pA45 backbone (Fig. 1) . Site-specific nucleotide substitutions were introduced into ORF5 of ATCC, UCD, and MLV vaccine strains of EAV (5rATCC, 5rUCD, and 5rVAC, respectively; Tables 1 and 6, Fig. 2b ) using a standard site-directed mutagenesis protocol described by Landt et al. (1990) . Restriction fragments containing the engineered mutation(s) were first cloned into the pS45 shuttle vector using restriction sites (NotI and EcoRI) and then transferred to the full-length clone as described above.
In vitro transcription and generation of recombinant viruses
Run-off RNA transcripts were generated in vitro as previously described from each chimeric/mutant infectious cDNA clone after linearization with restriction enzyme XhoI (van Dinten et al., 1997) . Full-length RNA transcripts were transfected into BHK-21 cells by electroporation as previously described (Balasuriya et al., 1999a (Balasuriya et al., , 1999b van Dinten et al., 1997) . Cells were incubated at room temperature for 10 min after electroporation and mixed with 12 ml of complete BHK-21 medium warmed to room temperature. The cells were seeded onto 10 cm diameter tissue culture plates (Falcon) and incubated at 37 jC for 48 -72 h until cytopathic effect (CPE) was evident. For immunofluorescence assays, electroporated BHK-21 cells were directly seeded onto glass coverslips and incubated at 37 jC for 12 -20 h. Monospecific rabbit anti-peptide serum to the nsp3, and MAb 3E2 to the N protein were used to detect virus replication and expression of specific proteins in the electroporated BHK-21 cells by immunofluorescence staining as previously described (van der Meer et al., 1998) . Tissue culture fluid (TCF) was harvested and centrifuged at 400 Â g for 10 min at 4 jC. Each chimeric/mutant virus was passaged three more times on BHK-21 cells to make working stocks and the titer of each virus was determined as tissue culture infectious doses (TCID 50 ) using RK-13 cells as the indicator cells. The virus titers of the stocks ranged from 10 4.5 to 10 6.5 TCID 50 units per 50 Al.
RT-PCR amplification and sequencing of ORF5 of recombinant viruses
The authenticity of the ORF5 insert in each chimeric/ mutant virus stock was determined by RT-PCR amplification and sequencing of the entire gene from RNA that was isolated from TCF from passage three of each virus (Balasuriya et al., 1999a (Balasuriya et al., , 1999b . Briefly, RNA was directly isolated from the TCF using the QIAmp viral RNA isolation kit (Qiagen). The purified RNA was treated with DNase I (Ambion) for 30 min at 37 jC to remove any contaminating plasmid DNA before RT-PCR amplification. The RT-PCR amplification and sequencing of ORF5 was done as previously described (Balasuriya et al., 1995a (Balasuriya et al., , 1995b Hedges et al., 1996) . Sequence data were collected and edited with an ABI 377 Automatic Sequencer (Applied Biosystems) according to the manufacturer's instructions. Nucleotide and amino acid sequence data were analyzed using Sequencher 3.0 (Gene Codes Corp.) and HIBIO MacDNASIS Pro Version 3.5 software (Hitachi Software Engineering Co., Ltd.).
Microneutralization assay
All viruses were characterized by microneutralization assay as previously described (Balasuriya et al., 1995a (Balasuriya et al., , 1995b (Balasuriya et al., , 1997 . Neutralization titers were determined for each laboratory, field, vaccine, and chimeric/mutant strain of EAV using all of the various MAbs and polyclonal equine antisera (Table 2) .
